Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

NCT02636582 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

NIH

Sponsor class

Conditions

Breast Ductal Carcinoma In Situ

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Nelipepimut-S Plus GM-CSF Vaccine
BIOLOGICAL: Sargramostim
PROCEDURE: Surgical Procedure

Sponsor

National Cancer Institute (NCI)